Serodiagnosis of Borreliosis: Indirect Immunofluorescence Assay, Enzyme-Linked Immunosorbent Assay and Immunoblotting

Iwona Wojciechowska-Koszko1, Iwona Mączyńska1, Zbigniew Szych2, Stefania Giedrys-Kalemba1
1Department of Microbiology and Immunology, Pomeranian Medical University, Szczecin, Poland
2Department of Informatics and Biocybernetics, Pomeranian Medical University, Szczecin, Poland

Tóm tắt

Lyme disease is an infectious, multi-system, tick-borne disease caused by genospecies of Borrelia burgdorferi bacteria sensu lato, characterized by remarkable heterogeneity. In this situation choosing an optimal antigen array for diagnostic tests seems problematic. The serological tests for borrelia routinely done in laboratories often produce ambiguous results, which makes a proper diagnosis rather complicated and thus delays the implementation of an appropriate treatment regimen. Thirty-seven outpatients and eight inpatients with suspected borreliosis diagnosis hospitalized at the Clinics of the Pomeranian Medical University (Szczecin, Poland), participated in the study. In order to detect the antibodies against Borrelia sensu lato three kinds of serological tests were used: indirect immunofluorescence assay (IIFA), enzyme-linked immunosorbent assay (ELISA), and immunoblot. The IIFA and immunoblot tests conducted on 45 patients (100%) produced positive results for both the IgM and IgG antibody types. In the case of ELISA, positive or borderline results were observed in only 24 patients (53.3%). The immunoblot test for IgM most frequently detected antibodies against the outer surface protein C (OspC) antigen (p25), and, in the case of IgG, against the recombinant variable surface antigen (VlsE). The IIFA screening test used for diagnosing Lyme borreliosis produced the highest percentage of positive results, which were then confirmed by immunoblot, but not by ELISA. Therefore using only ELISA as a screening test or for diagnosing Lyme borreliosis seems debatable.

Tài liệu tham khảo

Aberer E (2007) Lyme borreliosis—an update. J Dtsch Dermatol Ges 5:406–413 Aguero-Rosenfeld ME, Wang G, Schwartz I et al (2005) Diagnosis of lyme borreliosis. Clin Microbiol Rev 18:484–509 Altpeter ES, Meier C (1992) Epidemiologische Aspekte der Neurologischen Komplikationen der Lyme-Borreliose in der Schweiz. Schweiz Med Wochenscher 122:22–26 Cetin E, Sotoudeh M, Auer H, Stanek G (2006) Paradigm Burgenland: risk of Borrelia burgdoferi sensu lato infection indicated by variable seroprevalence rates in hunters. Wien Klin Wochenschr 118:677–681 Chmielewska-Badora J, Cisak E, Wójcik-Fatla A et al (2006) Correlation of tests for detection of Borrelia burgdorferi sensu lato infection in patients with diagnosed borreliosis. Ann Agric Environ Med 13:307–311 Figlerowicz M (2006) Borelioza–pamiątka z wakacji. Przew Lek 8:56–59 Glatz M, Fingerle V, Wilske B et al (2008) Immunoblot analysis of seroreactivity to recombinant Borrelia burgdorferi sensu lato antigens, including VlsE, in the long-term course of treated patients with erythema migrans. Dermatology 216:93–103 Hauser U, Lehnert G, Lobentanzer R, Wilske B (1997) Interpretation criteria for standardized Western Blots for three European species of Borrelia burgdorferi sensu lato. J Clin Microbiol 35:1433–1444 Marangoni A, Sparacino M, Mondardini V et al (2005) Comparative evaluation of two enzyme linked immunosorbent assay methods and three Western Blot methods for the diagnosis of culture-confirmed early Lyme Borreliosis in Italy. New Microbiol 28:37–43 Niścigorska J, Skotarczak B, Wodecka B (2003) Borrelia burgdorferi infection among forestry workers—assessed with an immunoenzymatic method (ELISA), PCR, and correlated with the clinical state of the patients. Ann Agric Environ Med 10:15–19 Sigal LH (1992) Current recommendations for the treatment of Lyme disease. Drugs 43:683–699 Stanek G, Strle F (2009) Lyme borreliosis: a European perspective on diagnosis and clinical management. Curr Opin Infect Dis 22:450–454 Steere AC (1989) Lyme disease. N Engl J Med 321:586–596 Tylewska-Wierzbanowska S, Chmielewski T (2005) Serological diagnosis of Lyme disease—European guidelines. Postepy Mikrobiol 44:289–293 Wilske B (2003) Diagnosis of Lyme borreliosis in Europe. Vector Borne Zoonotic Dis 3:215–227 Wilske B, Fingerle V, Herzer P et al (1993) Recombinant immunoblot in the serodiagnosis of Lyme borreliosis. Comparison with indirect immunofluorescence and enzyme-linked immunosorbent assay. Med Microbiol Immunol 182:255–270 Wilske B, Fingerle V, Schulte-Spechtel U (2007) Microbiological and serological diagnosis of Lyme borreliosis. FEMS Immunol Med Microbiol 49:13–21 Zajkowska J, Kondrusik M, Pancewicz S et al (2006) [Western-blot with VLSE protein and “in vivo” antigens in Lyme borreliosis diagnosis]. In Polish. Przegl Epidemiol 60(suppl 1):177–185 Zajkowska JM, Kondrusik M, Pancewicz SA et al (2007) Comparison of test with antigen VlsE (C6) with tests with recombinant antigens in patients with Lyme borreliosis. Pol Merkur Lekarski 23:95–99 in Polish